Gastrointestinal symptoms, including nausea, vomiting, and reflux, were the most common adverse events and were more frequent in semaglutide recipients
Ozempic is FDA approved for type 2 diabetes
CagriSema FDA approval timeline Novo Nordisk submitted the New Drug Application (NDA) to the FDA on December 18, 2025 , for chronic weight management in adults with obesity or overweight with a weight-related comorbidity
You should come away from the appointment with a clear sense of how the dosage will be titrated, best ways to manage side effects, and when to call with concerns
Products advertised online as Retatrutide outside legitimate clinical research may have unverified ingredients, strength, purity, sterility, or dosing